m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC

Myc-tagged YAP, YTHDF1, YTHDF2, YTHDF3 and Flag-tagged ALKBH5, YTHDF1, YTHDF2, YTHDF3 constructs were made using the pcDNA 3.1 vector (Invitrogen, Carlsbad, CA, USA). Sequences encoding the Myc epitope (EQKLISEEDL) and Flag epitope (DYKDDDDK) were added by PCR through replacement of the first Met-encoding codon in the respective cDNA clones.

Human lung normal cell line BEAS-2B and NSCLC cell lines A549, H1299, Calu6 and H520 were purchased from American Type Culture Collections (Manassas, VA). Cell lines were cultivated in RPMI-1640 medium supplemented with 10% FBS (Hyclone, USA), penicillin/streptomycin (100 mg/mL). Culture flasks were kept at 37 °C in a humid incubator with 5% CO₂.

We used TRIzol reagent (TransGen Biotech, Beijing, China) to isolate total RNA from the samples. RNA was reverse transcribed into first-strand cDNA using a TransScript All-in-One First-Strand cDNA Synthesis Kit (TransGen Biotech). cDNAs were used in RT-PCR and quantitative real-time PCR assay with the human GAPDH gene as an internal control. The final quantitative real-time PCR reaction mix contained 10 μL Bestar® SYBR Green qPCR Master Mix, Amplification was performed as follows: a denaturation step at 94 °C for 5 min, followed by 40 cycles of amplification at 94 °C for 30 s, 58 °C for 30 s and 72 °C for 30 s. The reaction was stopped at 25 °C for 5 min. The relative expression levels were detected and analyzed by ABI Prism 7900HT/FAST (Applied Biosystems, USA) based on the formula of 2^-ΔΔct. RT-PCR analysis of miR-107 was conducted with One step miRNA RT kit (D1801, HaiGene, China) for reverse-transcription. The PCR was performed with the Dream taq Green master mix (Fermentas, K1082) following the manufacturer’s protocols, then used the 4% agarose gel at 120 V for 70 min. We got the images of RT-PCR by Image Lab™ Software (ChemiDocTM XRS+, BiO-RAD) and these images were TIF with reversal color format. Primers for qPCR:

ALKBH5 forward primer: 5′-GCCTATTCGGGTGTCGGAAC-3′.

ALKBH5 reverse primer: 5′-CTGAGGCCGTATGCAGTGAG-3′.

YTHDF1 forward primer: 5′-GCACACAACCTCCATCTTCG-3′.

YTHDF1 reverse primer: 5′-AACTGGTTCGCCCTCATTGT-3′.

YTHDF2 forward primer: 5′-TCTGGAAAAGGCTAAGCAGG-3′.

YTHDF2 reverse primer: 5′-CTTTTATTTCCCACGACCTTGAC-3′.

YTHDF3 forward primer: 5′-TGACAACAAACCGGTTACCA-3′.

YTHDF3 reverse primer: 5′-TGTTTCTATTTCTCTCCCTACGC-3′.

YAP forward primer: 5′-GGATTTCTGCCTTCCCTGAA-3′.

YAP reverse primer: 5′-GATAGCAGGGCGTGAGGAAC-3′.

Cyr61 forward primer: 5′-GGTCAAAGTTACCGGGCAGT-3′.

Cyr61 reverse primer: 5′-GGAGGCATCGAATCCCAGC-3′.

CTGF forward primer: 5′-ACCGACTGGAAGACACGTTTG-3′.

CTGF reverse primer: 5′-CCAGGTCAGCTTCGCAAGG-3′.

HuR forward primer: 5′-CGGAATTCAATACAATGTCTAATGG-3′.

HuR reverse primer: 5′-GGGGTACCATTGGCGCAAAATGAG-3′.

LATS2 forward primer: 5′-CAGGATGCGACCAGGAGATG-3′.

LATS2 reverse primer: 5′-CCGCACAATCTGCTCATTC-3′.

E-cadherin forward primer: 5′-ACCATTAACAGGAACACAGG − 3′.

E-cadherin reverse primer: 5′-CAGTCACTTTCAGTGTGGTG-3′.

Vimentin forward primer: 5′- CGCCAACTACATCGACAAGGTGC-3′.

Vimentin reverse primer: 5′-CTGGTCCACCTGCCGGCGCAG-3′.

GAPDH forward primer: 5′-CTCCTCCTGTTCGACAGTCAGC-3′.

GAPDH reverse primer: 5′-CCCAATACGACCAAATCCGTT-3′.

miR-107 forward primer: 5′- GCCGAATTCAAAGCGAGATTCCATCAGCA-3′.

miR-107 reverse primer: 5′- GCCGGATCCTGTCAACCCAGAACTCAAAGG-3′.

Human lung cancer cells were transfected with the relevant plasmids and cultured for 48 h. For western blot analysis, cells were lysed in NP-40 buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 1 mM PMSF, and 0.5% NP-40) at 25 °C for 40 min. The lysates were added to 5× loading dye and then separated by electrophoresis. The primary antibodies used in this study were 1:1000 rabbit anti-Flag (sc-166,384, Santa Cruz, Dallas, TX, USA) and 1:1000 Abcam (Cambridge, UK) antibody of Myc (ab32072), ALKBH5 (ab234528), YAP (ab56701), YTHDF1 (ab220162), YTHDF2 (ab220163), YTHDF3 (ab220161), HuR (ab200342), LATS2 (ab135794), CTGF (ab6992), Cyr61 (ab24448), AGO2 (ab32381), eIF3a (ab86146), Vimentin (ab45939), E-cadherin (ab1416), cleaved Capase-3 (ab32042) and Tubulin (ab6046).

Tumor tissues were fixed in 4% paraformaldehyde overnight and then embedded in paraffin wax. Four-micrometer thick sections were stained using hematoxylin and eosin (H&E) for histological analysis.

Overexpressing plasmid (2 μg), siRNA (1.5 μg) and shRNA (1.5 μg) of indicated genes were transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for over-expression and knockdown of indicated genes, followed by analysis 48–72 h later. The selected sequences for knockdown as follow:

shALKBH5–1: 5′-CCTCATAGTCGCTGCGCTCG-3′.

shALKBH5–2: 5′-ATAGTTGTCCCGGGACGTCA-3′.

siYAP-1: 5′- AAGGTGATACTATCAACCAAA-3′.

siYAP-2: 5′- AAGACATCTTCTGGTCAGAGA-3′.

siALKBH5–1: 5′-ACAAGTACTTCTTCGGCGA-3′.

siALKBH5–2: 5′-GCGCCGTCATCAACGACTA-3′.

siYTHDF1–1: 5′-CCGCGTCTAGTTGTTCATGAA-3′.

siYTHDF1–2: 5′-CCTCCACCCATAAAGCATA-3′.

siYTHDF2–1: 5′-CTGCCATGTCAGATTCCTA-3′.

siYTHDF2–2: 5′-GCTCCAGGCATG AATACTATA-3′.

siYTHDF3–1: 5′-GGACGTGTGTTTATAATTA-3′.

siYTHDF3–2: 5′-GACTAGCATTGCAACCAAT-3′.

siAGO2: 5′-GCACGGAAGTCCATCTGAA-3′.

sieIF3a: 5′-CAGTTGATGGCAAATTACT-3′.

siHuR: 5′-TGTCAAACCGGATAAACGC-3′.

sicontrol: 5′-TTCTCCGAACGTGTCACGA-3′.

shcontrol: 5′-ACGTGACACGTTCGGAGAATT-3′.

Cell viability and growth was determined using CCK8 assays in 96-well plates. Cells were transfected with the relevant plasmids culturing for 48 h, followed by incubation with 10 μL CCK8 for 4 h. Absorbance was read at 450 nm using a spectrophotometer (Tecan, Männedorf, Switzerland).

To examine the protein expression and location by immunofluorescent staining, NSCLC cells were seeded onto coverslips in a 24-well plate and left overnight. Cells were then fixed using 4% formaldehyde for 30 min at 25 °C and treated with 3% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 30 min. The coverslips were incubated with rabbit anti-ALKBH5, YTHDF1, YTHDF2, YTHDF3, YAP, CTGF, Cyr61, Ki67, Annexin V, Ki67, Edu, Vimentin and mouse anti-E-cadherin monoclonal antibody (Abcam) at 1:200 dilution in 3% BSA. Alexa-Fluor 488 (green, 1:500, A-11029; Invitrogen, USA) and 594 (red, 1:500, A-11032; Invitrogen, USA) tagged anti-rabbit or -mouse monoclonal secondary antibody at 1:1000 dilution in 3% BSA. Hoechst (3 μg/mL, cat. no. E607328; Sangon Biotech Co., Ltd.) was added for nuclear counterstaining. Six pictures were obtained with a Zeiss Axio Imager Z1 Fluorescent Microscope (Zeiss, Oberkochen, Germany). The results were presented as the Mean ± SD.

Transfected A549 and H1299 cells were harvest in PBS and resuspended for 10 min on ice in 500 μL CLB Buffer (10 mM Hepes, 10 mM NaCl, 1 mM KH₂PO₄, 5 mM NaHCO₃, 5 mM EDTA, 1 mM CaCl₂, 0.5 mM MgCl₂). Thereafter, 50 μL of 2.5 M sucrose was added to restore isotonic conditions. The first round of centrifugation was performed at 6300 g for 5 min at 4 °C. The pellet washed with TSE buffer (10 mM Tris, 300 mM sucrose, 1 mM EDTA, 0.1% NP40, PH 7.5) at 1000 g for 5 min at 4 °C until the supernatant was clear. The resulting pellets were nucleus. The resulting supernatant from the first round was transferred and subjected to differential centrifugation at 14000 rpm for 30 min. The resulting pellets were membranes and the supernatant were cytoplasm.

RNA immunoprecipitation (RIP) was performed using Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore) according to the manufacturer′s instructions. Briefly, cells were collected and lysed in complete RIPA buffer containing a protease inhibitor cocktail and RNase inhibitor. Next, the cell lysates were incubated with RIP buffer containing magnetic bead conjugated with indicated antibody (Abcam) or control normal human IgG. The samples were digested with proteinase K to isolate the immunoprecipitated RNA. The purified RNA was finally subjected to qPCR to demonstrate the presence of the binding targets.

Harvested cells were rinsed and sonicated in NET-2 buffer (50 mM Tris-HCl, pH 7.4, 150–300 mM NaCl, 0.05% NP40, PMSF, Benzamidine). Cell lysates were incubated with biotin-labeled probes synthesized from Sangon (Shanghai, China), and then pulled down with streptavidin beads (Sigma-Aldrich). Precipitated RNA and proteins were subsequently subjected to RT-PCR and western blot analyses, respectively.

The MS2 coat protein system was performed as described previously [25]. Briefly, stably expressed pcDNA3.1-YAP-MS2–12X (YAP-MS2) NSCLC cells were co-transfected with pcDNA3.1-MS2-GFP and relevant pcDNA3.1-YTHDFs then cultivated in RPMI-1640 medium supplemented with 10% FBS (Hyclone, USA), penicillin/streptomycin (100 mg/mL). Culture flasks were kept at 37 °C for 48 h in a humid incubator with 5% CO₂. The cell lysate from these transfected cells were immunoprecipitated by GFP antibody to enrich YAP mRNA then performed the following experiment.

The total m⁶A content of Total RNA was determined using an m⁶A methylation quantification kit (EpiGentek, USA). Briefly, after total RNA was isolated and purified, the bind RNA was planted to the assay wells and cultured with the capture antibody. After that, the wells were washed, and the detection antibody and enhancer solution were added. The m⁶A level was detected according to the fluorescence after the wells were incubated with the fluoro developer solution.

mRNA was isolated from total RNA by using a Dynabeads mRNA Purification Kit (Thermo Fisher Scientific), and rRNA contaminants were removed by using a RiboMinus Eukaryote Kit (Thermo Fisher Scientific). Subsequently, mRNA was digested into nucleosides by using nuclease P1 and alkaline phosphatase and was then filtered with a 0.22 mm filter. The amount of m⁶A was measured according to HPLC–tandem mass spectrometry, following the published procedure [26]. Quantification was performed by using the standard curve obtained from pure nucleoside standards that were run with the same batch of samples. The ratio of m⁶A to A was calculated based on the calibrated concentrations.

m⁶A Ribonucleoprotein Immunoprecipitation reactions were performed by first isolating PolyA+ RNA from treated NSCLC cells. Protein G Dynabeads (Thermo Fisher Scientific, Baltics UAB) were washed 3× in 1 mL of IPP buffer (10 mM Tris-HCL pH 7.4, 150 mM NaCl, 0.1% NP-40). 25 μl of beads required per IP. Anti-N⁶-methyladenosine human monoclonal antibody (EMD Millipore, Temecula, CA, MABE1006) was added to the beads (5 μg/IP) and brought up to 1 mL with IPP buffer. Bead mixture was tumbled for 16 h at 4 °C. Beads were washed 5× with IPP buffer and 100 ng of PolyA+ RNA was added to the beads along with 1 mM DTT and RNase out. The mixture was brought up to 500 μl with IPP buffer. Bead mixture was tumbled at 4 °C for 4 h. Beads were washed 2× in IPP buffer, placed into a fresh tube, and washed 3× more in IPP buffer. m⁶A RNA was eluted off the beads by tumbling with 125 μl of 2.5 mg/mL N⁶-Methyladenosine-5′-monophosphate sodium salt (CHEM-IMPEX INT’L INC., Wood Dale, IL). Supernatant was added to Trizol-LS followed by RNA isolation as manufacture’s protocol. Final RNA sample was brought up in 10 μl of water.

Reverse transcription was performed on 10 μl m⁶A PolyA+ RNA from the MeRIP with the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). After diluting cDNA two-fold, quantitative real-time PCR was performed using the ABI Prism 7900HT/FAST (Applied Biosystems, USA) and primers from Integrated DNA Technologies, Inc. (Coralville, Iowa). Primers used are listed in the follows. Primer efficiency was verified to be over 95% for all primer sets used. Quantification of mRNA from the MeRIP was carried out via 2^-ΔΔct. analysis against non-immunoprecipitated input RNA. All real-time PCR primer sets were designed so the products would span at least one intron (> 1 kb when possible), and amplification of a single product was confirmed by agarose gel visualization and/or melting curve analysis. Primers for MeRIP:

YAP m⁶A peak1 Forward primer: 5′-TGCGCGTCGGGGGAGGCAGAAG-3′.

YAP m⁶A peak1 Reverse primer: 5′-GGAATGAGCTCGAACATGCTG-3′.

YAP m⁶A peak2 Forward primer: 5′-TGAACCAGAGAATCAGTCAGAG-3′.

YAP m⁶A peak2 Reverse primer: 5′-GTACTCTCATCTCGAGAGTG-3′.

YAP m⁶A peak3 Forward primer: 5′-CCAGTGTCTTCTCCCGGGATG-3′.

YAP m⁶A peak3 Reverse primer: 5′-TATCTAGCTTGGTGGCAGCC-3′.

A549 and H1299 cells were transfected with relevant plasmids and cultured for indicated times. For ELISA analysis, the YAP (Human) Cell-Based ELISA Kit (KA3582, Abnova, Taiwan, China) was used to detect the YAP protein expression following the manufacturer’s protocols. Briefly, fixing Solution, Quenching Buffer, Blocking Buffer, 1x primary antibodies were orderly added into the fixed cells and incubate overnight at 4 °C then add 50 μl of HRP-conjugated secondary antibodies and incubate for 1.5 h at room temperature and add 50 μl of TMB One-Step Reagent and incubate for 30 min at room temperature. Absorbance was read at 450 nm using a spectrophotometer (Tecan, Männedorf, Switzerland).

To analyze correlation between ALKBH5, YAP, YTHDF1, YTHDF2 and YTHDF3 expression level and prognostic outcome of patients, Kaplan-Meier survival curves of NSCLC patients with low and high expression of ALKBH5, YAP, YTHDF1, YTHDF2 and YTHDF3 were generated using Kaplan-Meier Plotter (www.kmplot.com/analysis↗ and www.oncolnc.org↗) [27].

All the human lung cancer and normal lung specimens were collected in Affiliated Hospital of Binzhou Medical College with written consents of patients and the approval from the Institute Research Ethics Committee.

To assess the in vivo effects of ALKBH5, 3 to 5-week old female BALB/c athymic (NU/NU) nude mice were housed in a level 2 biosafety laboratory and raised according to the institutional animal guidelines of Binzhou Medical University. All animal experiments were carried out with the prior approval of the Binzhou Medical University Committee on Animal Care. For the experiments, mice were injected with 5 × 10⁶ lung cancer cells with stably expression of relevant plasmids and randomly divided into indicated groups (five mice per group). To assess the in vivo effects of cycloleucine, the xenografted tumors had reached approximately 5 mm in diameter from mice and then these xenografted mice were feed with Vehicle or cycloleucine (25 mg/kg twice weekly) and tumor volume were measured every 3 day. Tumor volume was estimated as 0.5 × a² × b (where a and b represent a tumors short and long diameter, respectively). Mice were euthanized after 7 weeks and the tumors were measured a final time. Tumor and organ tissue were then collected from xenograft mice and analyzed by immunohistochemistry.

Each experiment was repeated at least three times. The statistical analyses of the experiment data were performed by using a two-tailed Student’s paired T-test and one-way ANOVA. Statistical significance was assessed at least three independent experiments and significance was considered at either P-value < 0.05 was considered statistically significant and highlighted an asterisk in the figures, while P-values < 0.01 were highlighted using two asterisks and P-values < 0.001 highlighted using three asterisks in the figures.

For the study, NSCLC samples were obtained from patients who underwent lung resection surgery at the Affiliated Hospital of Binzhou Medical University (Binzhou, China) between January 2018 and January 2019. The clinicopathological findings of ALKBH5, YAP, YTHDF1 and YTHDF2 expressions in the samples and pathological grades of NSCLC patients are summarized in Table 1 and Additional file 1: Table S1. We found that YAP expression was negatively correlated with ALKBH5 expression in NSCLC tumor tissues (Table 1). Interestingly, opposite trends of YAP and ALKBH5 expression were observed in paired fresh NSCLC tumor cancer tissues (Tumor) and matched adjacent normal tissues (Normal) by RT-PCR, western blotting, and qPCR (left panel, n = 10; right panel, n = 30) (Fig. 1a, Additional file 2: Fig. S1a, b, n = 10), and immunohistochemistry (IHC) (Fig. 1b, n = 10). Concurrently, TCGA database (https://www.cancer.gov↗) analysis revealed similar results (Fig. 1c). We also found that the mRNA and protein levels of YAP were higher, while those of ALKBH5 were lower, in NSCLC cancer cells than in the control (normal) cells BEAS-2B (Fig. 1d, Additional file 2: Fig. S1c). Next, publicly available datasets were screened and used to determine the prognostic correlation between YAP/ALKBH5 expression and NSCLC patient survival [27]. Results show that the overall survival (OS) time of patients with high YAP expression (n = 246) was shorter than that of patients with low YAP expression (n = 246) (P = 0.00932) whereas OS time of patients with low ALKBH5 expression (n = 246) was shorter than that of patients with high ALKBH5 expression (n = 246) (P = 0.00545) [27](Fig. 1e). These observations suggest that deregulated expression of YAP and ALKBH5 is closely associated with the occurrence and development of NSCLC.

To investigate the function of YAP and ALKBH5 in NSCLC cells, we then used siRNAs and shRNAs to knock down YAP (siYAP-1 and siYAP-2) and ALKBH5 (shALKBH5–1 and shALKBH5–2), or overexpressed these genes by transfecting A549 and H1299 cells with a plasmid encoding Myc-YAP or Flag-ALKBH5, accordingly (Fig. 1f, Additional file 2: Fig. S1d, e). Knocking down YAP using siYAP-2 and ALKBH5 using shALKBH5–1 was more effective than siYAP-1 and shALKBH5–2 (Additional file 2: Fig. S1f, g). Therefore, siYAP-2 and shALKBH5–1 were used in subsequent knockdown experiments. CCK8 analysis revealed that overexpression of YAP and knockdown of ALKBH5 enhanced cellular growth and viability, while knockdown of YAP and overexpression of ALKBH5 reduced cellular growth and viability (Fig. 1g, Additional file 2: Fig. S1h, i). Ki67/Edu (commonly used as a proliferation indicator) staining (Additional file 2: Fig. S1j, k), analysis of the protein levels of cleaved caspase 3 (commonly used as an apoptosis indicator) (Additional file 2: Fig. S1l, m), and clone formation assays (Additional file 3: Fig. S2a) confirmed these findings. Similar results for cellular migration and invasion growth were obtained with A549 and H1299 cells, as detected by scratch and transwell assays (Fig. 1h, i, Additional file 3: Fig. S2b-e). Further, to assess the role of YAP and ALKBH5 in EMT, we evaluated variations in E-cadherin and Vimentin levels associated with the YAP and ALKBH5 status. RT-PCR, western blotting, and immunofluorescence analyses showed that YAP silencing and ALKBH5 overexpression decreased mRNA and protein levels of Vimentin, and increased those of E-cadherin in A549 and H1299 cells; the opposite result was observed upon YAP overexpression and ALKBH5 silencing (Fig. 1j, Additional file 3: Fig. S2f, g). Furthermore, spearman rank correlation analysis of data in the TCGA database revealed positive correlations between YAP and Vimentin levels, and ALKBH5 and E-cadherin levels, but negative correlations between YAP and E-cadherin levels, and ALKBH5 and Vimentin levels (Additional file 3: Fig. S2h, i). These observations indicated that YAP expression is negatively correlated with ALKBH5 expression, and that ectopic expression of YAP and ALKBH5 regulates cellular proliferation, invasion, migration, and EMT in NSCLC cells.

Furthermore, to explore ALKBH5 reduction of cell growth, migration and EMT via regulation of YAP, A549 and H1299 cells were solely transfected with ALKBH5 or co-transfected with ALKBH5 and YAP (Additional file: Fig. S3a). Data analysis showed that cell viability was increased in A549 and H1299 cells with co-transfection with ALKBH5 and YAP compared to the transfection with ALKBH5 alone (Additional file: Fig. S3b). Moreover, similar results for clone formation (Additional file: Fig. S3c) and migration (Additional file: Fig. S3d) were observed in A549 and H1299 cells with the same treatment. The EMT was increased in A549 and H1299 cells co-transfected with ALKBH5 and YAP compared to the ALKBH5 only transfection by detecting the EMT-related marker, E-cadherin and Vimentin, respectively (Additional file: Fig. S3e). These findings indicate that ALKBH5 decreases cell growth, migration and EMT via regulation of YAP in A549 and H1299 cells. 4 4 4 4 4

Recently, m⁶A modification of mRNA was shown to cause many tumors and diseases in mammals by regulating cell differentiation, tissue development, and tumorigenesis [28]. Therefore, we next explored whether m⁶A was involved in the occurrence and development of NSCLC. To verify the specific occurrence of m⁶A in transcripts in NSCLC cancer tissues and normal adjacent tissues, m⁶A peaks were analyzed by HPLC-tandem mass spectrometry, and categorized based on the annotation of gene and non-overlapping segments, as shown in Fig. 2a. Gene ontology enrichment analysis revealed that the m⁶A genes enriched in tumors were primarily involved in the regulation of cell proliferation, growth factor stimulus, and cell cycle process, i.e., the same phenomena that were affected by YAP overexpression [29] (Fig. 2b). We also observed that the m⁶A modification of total RNA (Fig. 2c, d), especially YAP m⁶A levels (Fig. 2c, Additional file 5: Fig. S4a), was higher in NSCLC tumor cancer tissues and cell lines than in their matched adjacent normal tissues and the control cells BEAS-2B. These findings revealed that m⁶A modification of YAP plays a major role in the occurrence and development of NSCLC. Importantly, RNA immunoprecipitation (RIP) assay revealed that YAP pre-mRNA interacted with ALKBH5 in A549 and H1299 cells (Fig. 2e, Additional file 5: Fig. S4b). Further, ALKBH5 overexpression and knockdown decreased or increased the levels of m⁶A modification of YAP pre-mRNA, respectively, compared with modification levels of control vectors of ALKBH5 in A549 and H1299 cells (Fig. 2f, Additional file 5: Fig. S4c). Similar results were obtained in A549 and H1299 cells for another m⁶A demethylase, FTO (Additional file 5: Fig. S4d). These findings indicate that ALKBH5 decreases the m⁶A levels on YAP pre-mRNA in NSCLC.

MeRIP combined with high throughput sequencing analysis of lung cancer tissues and normal adjacent lung tissues yielded m⁶A peaks within thousands of coding transcripts with high confidence (http://m6avar.renlab.org/↗). Consensus motif search identified GGACU sequence (Fig. 2g), which a consensus methylation motif reported by others [30]. We have identified three potential consensus motifs in CDS of YAP (Fig. 2h, upper panel). To investigate the role of these motifs regulated by ALKBH5, we introduced a synonymous mutation at the putative m⁶A sites in the YAP coding region, as follows: YAP Muts series: YAP Mut1, YAP Mut2, and YAP Mut3 (fragments containing only one potential m⁶A site, which was mutated to form YAP Mut1/2/3, respectively); YAP Muts# series: YAP Mut1#, YAP Mut2#, and YAP Mut3# (fragments containing three potential m⁶A sites, wherein only one m⁶A site was mutated to form YAP Mut1#/2#/3#, respectively); and YAP Mut1–3(#) (fragment with three potential m⁶A sites mutated to form YAP Mut1–3(#)) (Fig. 2h, lower panel) [25]. Importantly, the RIP assay revealed that YAP-WT and YAP-Muts# pre-mRNAs both interacted with ALKBH5, indicating that the interaction between YAP-Muts# pre-mRNA and ALKBH5 was not affected by the mutation and ruled out the possibility that YAP-Muts# cannot directly interact with ALKBH5 to influence the detection of YAP m⁶A modification by ALKBH5 (Fig. 2i). We then evaluated the levels of YAP m⁶A modification in A549 and H1299 cells co-transfection with ALKBH5 and the YAP mutant genes by using meRIP-qPCR. As hypothesized, ALKBH5 decreased the m⁶A modifications of YAP WT and YAP Muts# (Mut1#, Mut2# and Mut3#) in A549 and H1299 cells compared to the ALKBH5 control vector. However, the reduction level of m⁶A modification was repressed in YAP Muts# compared to YAP WT due to the presence of m⁶A site mutation in YAP Muts#. Importantly, the m⁶A modification of YAP Mut1–3#, containing all m⁶A site mutation, was not decreased in A549 and H1299 cells with overexpression of ALKBH5 compared to ALKBH5 control vector (Fig. 2j, left panel). Moreover, the m⁶A modifications of YAP WT and Muts# (Mut1#, Mut2# and Mut3#) were increased in A549 and H1299 cells with transfection with shALKBH5 compared to ALKBH5 control vector. However, the m⁶A modification of YAP Mut1–3# was unchanged in A549 and H1299 cells with transfection of shALKBH5 compared to ALKBH5 control vector, due to the presence of all m⁶A site mutations in YAP Mut1–3# (Additional file 5: Fig. S4e, left panel). Interestingly, the m⁶A modifications of YAP were unchanged in YAP Muts-transfected A549 and H1299 cells with co-transfection of ALKBH5 or shALKBH5 compared to ALKBH5 control vector, since that the only m⁶A modification site of YAP Muts was mutated (Fig. 2j, right panel, Additional file 5: Fig. S4e, right panel). This indicated that the predicted sites were indeed modified by m⁶A. These findings suggested that ALKBH5 directly interacts with YAP pre-mRNA and that this interaction decreases the level of m⁶A modification on YAP pre-mRNA.

To further investigate how m⁶A modification affects YAP expression, YAP mRNA and protein levels were evaluated in A549 and H1299 cells. We found that YAP mRNA and protein levels were higher in cells co-transfected with shALKBH5 and YAP-WT than in cells co-transfected with shALKBH5 and YAP-Muts# (Fig. 2k, Additional file 5: Fig. S4f). Additionally, YAP mRNA and protein levels, as well as the levels of YAP target genes, including CTGF and Cyr61, were significantly decreased in A549 and H1299 cells with ectopic ALKBH5 expression; the opposite was observed in cells upon shALKBH5 expression (Fig. 2l, Additional file 5: Fig. S4g-j). Further, IHC staining revealed that YAP protein levels were higher in tissues with low ALKBH5 expression (Additional file 5: Fig. S4k, l). TCGA database analysis revealed that ALKBH5 expression was negatively correlated with YAP expression (Fig. 2m). This suggested that ALKBH5 decreased YAP expression by regulating m⁶A level in NSCLC. We also performed tethering experiments using plasmids encoding either wild-type or a dominant catalytic variant (ALKBH5 KD: H204A) of ALKBH5 (Fig. 2n, left panel). The mRNA and protein levels of ALKBH5 KD were unchanged compared with those of ALKHB5 WT, which indicated that the mutation of ALKBH5 did not affect the expression of ALKBH5 (Fig. 2n, right panel, Additional file 5: Fig. S4m). Further, the interaction between YAP pre-mRNA and ALKBH5 KD was not affected by the substitution (Additional file 5: Fig. S4n). The m⁶A levels of YAP (Fig. 2o), and mRNA levels of YAP, CTGF, and Cyr61 (Fig. 2p) were insignificantly changed in A549 and H1299 cells transfected with plasmid encoding ALKBH5 KD compared with the control vector. These indicated that ALKBH5 directly binds to YAP pre-mRNA, decreases its m⁶A modification and reduces the expressions of YAP, CTGF and Cyr61, through which need the ALKBH5 catalytic activity in NSCLC.

When m⁶A of pre-mRNA is recognized by YTHDFs, either decay or translation of the mRNA is promoted, depending on the different YTHDFs involved. YTHDF3 serves as a hub to fine-tune the accessibility of RNA to YTHDF1 and YTHDF2 [15]. We therefore propose that YTHDF3 recognizes m⁶A modification of YAP pre-mRNA. YTHDF3 next was competitively bound by YTHDF1 or YTHDF2 passing the YAP pre-mRNA carrying the m⁶A modification to YTHDF3’s combinative partner. This may influence YAP expression in a reaction mediated by m⁶A modification of YAP pre-mRNA in the normal lung tissues and NSCLC tumor tissues (Fig. 3a). First, we observed that YTHDF1, YTHDF2, and YTHDF3 bind to YAP mRNA in A549 and H1299 cells (Fig. 3b). Additionally, increasing m⁶A modification by knocking down ALKBH5 significantly enhanced the interaction between YTHDF1/2/3 and YAP pre-mRNA, suggesting that YTHDF1/2/3 binding to YAP pre-mRNA is mediated by m⁶A modification (Fig. 3c). We then explored whether YTHDF1/2 interaction with YAP mRNA was affected by YTHDF3. Interestingly, RNA pulldown assays revealed that YTHDF1 or YTHDF2 binding to YAP mRNA was increased in the presence of YTHDF3, and less YTHDF1 or YTHDF2 bound YAP mRNA in the absence of YTHDF3 in A549 and H1299 cells (Fig. 3d, Additional file 6: Fig. S5a). We next explored whether YTHDF1 and YTHDF2 competitively bound YTHDF3. We found that ALKBH5 protein was only detectable in the nuclear fractions, enabling m⁶A modification of pre-mRNA (Fig. 3e, f). By contrast, YTHDFs proteins were localized only in the cytoplasmic fractions, in which YAP mRNA was destroyed or translated (Fig. 3e, g). However, the nuclear and cytoplasmic distribution of YAP Mut1–3 were not affected compared to YAP WT in A549 cells (Additional file 6: Fig. S5b, c). In addition, the endogenous co-IP experiments indicated that YTHDF1, YTHDF2, and YTHDF3 reciprocally and physically interacted with each other (Fig. 3h). Importantly, in A549 and H1299 cells, upon YTHDF1 overexpression, the interaction between YTHDF2 and YTHDF3 was inhibited; by contrast, when YTHDF2 was overexpressed, the interaction between YTHDF1 and YTHDF3 was inhibited (Fig. 3i). These observations indicated that YTHDF1 and YTHDF2 competitively bind YTHDF3 in NSCLC cells.

To investigated whether the m⁶A modification of YAP pre-mRNA was involved in the competition between YTHDF3 and both YTHDF1/2. First, we constructed the A549 and H1299 cells with stable expression of pcDNA3.1-YAP-MS2–12X (YAP-MS2) to utilize the MS2 coat protein system for enriching YAP mRNA (Additional file 6: Fig. S5d). Co-immunoprecipitation with western blotting analysis revealed that YTHDF1, YTHDF2, and YTHDF3 recognized m⁶A modification on YAP mRNA in A549 and H1299 cells (Fig. 3j, Additional file 6: Fig. S5e). Further, the amount of YTHDF1 and YTHDF2 proteins interacting with YAP pre-mRNA was decreased in A549 and H1299 cells after knocking down of YTHDF3 (Fig. 3k). Interestingly, increased m⁶A modification by shALKBH5 preferentially endow YTHDF1′s interaction with YAP pre-mRNA compared to YTHDF2 in A549 and H1299 cells (Fig. 3l). This indicated that the m⁶A on YAP pre-mRNA was first recognized by YTHDF3 and then YTHDF1 and YTHDF2 competitively bound YTHDF3 next YTHDF3 passes the YAP pre-mRNA carrying the m⁶A modification to YTHDF3’s combinative partner.

Finally, we explored whether the competitive relationship between YTHDF1/2 and YTHDF3 was dependent on the m⁶A modification regulated by ALKBH5. Firstly, the level of m⁶A modification on YAP pre-mRNA was unchanged in A549 and H1299 cells co-transfected with shALKBH5 and YTHDF3, shALKBH5 and YTHDF1/2, or shALKBH5 and YTHDF3&1/2, compared with the levels after the shALKBH5 only transfection (Fig. 3m). This indicated that YTHDFs did not increase the level of m⁶A modification of YAP pre-mRNA but only ALKBH5 with demethylase could regulate the m⁶A modification of YAP pre-mRNA. In addition, increasing the m⁶A modification level by shALKBH5 or decreasing the m⁶A modification level by ALKBH5 did not affect the interaction between YTHDF1/2 and YTHDF3, as revealed by Co-IP analysis (Fig. 3n, Additional file 6: Fig. S5f). These findings indicated that YTHDF1/2 competitively binds YTHDF3 independently of the m⁶A modification.

In summary, we found that m⁶A on YAP pre-mRNA was first recognized by YTHDF3, which then competitively bound YTHDF1 or YTHDF2 in an m⁶A-independent manner to regulate YAP expression. However, YTHDF1/2/3 binding to YAP pre-mRNA was mediated by the m⁶A modification.

Recent studies have shown that, m⁶A mediates two different fates of mRNA, i.e., by promoting the decay or translation of mRNA. We therefore investigated whether and how the YTHDF proteins, which recognize the m⁶A modification, control NSCLC growth and migration by regulating YAP pre-mRNA status. As shown in Fig. 3a, YTHDF2 competitively bound YTHDF3 to promote YAP mRNA decay under control conditions. As indicated above, the mRNA and protein levels of YTHDF2 were higher in the NSCLC normal tissues than in their paired tumor tissues (Fig. 4a, Additional file 7: Fig. S6a, b). In addition, YTHDF2 protein levels were gradually decreasing with the increasing grade of NSCLC tumor (Fig. 4b). The correlation of individual the protein level of YTHDF2 with pathological grades of NSCLC patients was shown in Table S1 (Additional file 1: Table S1). Further, the mRNA and protein levels of YTHDF2 were lower in NSCLC cancer cells than in the control cells BEAS-2B (Additional file 7: Fig. S6c). Next, we used the publicly available datasets to determine the prognostic correlation between YTHDF2 expression and NSCLC patient survival [27]. The results show that the OS of patients with low YTHDF2 expression (n = 246) was shorter than that of patients with high YTHDF2 expression (n = 246) (P = 0.021) (Fig. 4c). To investigate the function of YTHDF2 in NSCLC cells, we knocked down YTHDF2 using siYTHDF2–1 and siYTHDF2–2 (knocking down YTHDF2 using siYTHDF2–1 was more effective than siYTHDF2–2, so siYTHDF2–1 was used to carry out then subsequent experiments) or overexpressed the protein by transfecting A549 and H1299 cells with a plasmid encoding Flag-YTHDF2 (Fig. 4d, Additional file 7: Fig. S6d, e). Knocking down of YTHDF2 increased, while YTHDF2 overexpression decreased, the cellular growth and viability of A549 and H1299 cells, as determined by the CCK8 assay (Fig. 4e, Additional file 7: Fig. S6f), determining cleaved caspase 3 levels (Additional file 7: Fig. S6g) and Ki67 staining (Additional file 7: Fig. S6h). Similar effects on cell migration and invasion growth were obtained with A549 and H1299 cells, as determined by transwell and scratch assays (Fig. 4f, Additional file 7: Fig. S6i, j). Further, YTHDF2 overexpression in A549 and H1299 cells decreased mRNA and protein levels of Vimentin and increased those of E-cadherin, whereas the opposite was observed upon knocking down of YTHDF2 (Fig. 4g, Additional file 7: Fig. S6k). Furthermore, spearman rank correlation analysis of data in TCGA database revealed positive correlation between YTHDF2 and E-cadherin levels and negative correlation between YTHDF2 and vimentin levels (Additional file 7: Fig. S6l). These observations indicated that overexpression of YTHDF2 inhibits cellular proliferation, invasion, migration, and EMT in NSCLC cells.

Next, we explore the mechanism whereby YTHDF2 promoted to decay YAP mRNA. First, we observed that YTHDF2 overexpression further reduced ALKBH5-mediated decrease of YAP mRNA levels, while cell co-transfection with siAGO2 reduced this effect (Fig. 4h, Additional file 8: Fig. S7a). Importantly, endogenous co-IP experiments revealed that YTHDF2 bound to argonaute RISC catalytic component 2 (AGO2) (Fig. 4i). This indicated that after YTHDF2 binding to YTHDF3, which binds YAP pre-mRNA modified by m⁶A, YTHDF2 presented YAP mRNA to AGO2, followed by AGO2 recruitment of other molecules, including some microRNAs, to form RISC system to facilitate decay of YAP mRNA. To accurately evaluate the decay of YAP mRNA associated with YTHDF2, we analyzed mRNA degradation by qPCR in actinomycin D (ActD)-treated A549 and H1299 cells. We observed that the YAP mRNA was decreased with increasing concentrations of ActD, while YAP mRNA levels increased or decreased in ActD-treated A549 and H1299 cells after knock down or overexpression of YTHDF2, respectively, compared with the control vectors (Additional file 8: Fig. S7b). In addition, with increasing ActD-treatment time, the decay of YAP mRNA was increased or decreased in A549 and H1299 cells transfected with YTHDF2 or siYTHDF2, respectively, compared with the control vectors (Additional file 8: Fig. S7c, d). Further, the YAP mRNA degradation was increased or decreased in ActD-treated A549 and H1299 cells co-transfected with YTHDF2 and YTHDF3 or YTHDF2 and siYTHDF3, respectively, compared with the control (Fig. 4j, Additional file 8: Fig. S7e). The mRNA levels of YAP, CTGF, and Cyr61 also showed these trends in the transfected cells (Additional file 8: Fig. S7f). Similarly, the YAP mRNA degradation was increased or decreased in ActD-treated A549 and H1299 cells co-transfected with YTHDF2 and AGO2 or YTHDF2 and siAGO2, respectively, compared with the control (Fig. 4k). Furthermore, YTHDF2-associated YAP mRNA degradation was increased in cells with decreased m⁶A status regulated by ALKBH5 but decreased in cells with increased m⁶A status regulated by shALKBH5 in NSCLC cells (Fig. 4l). Finally, the m⁶A-mediated YAP mRNA decay was increased upon co-transfection with YTHDF2 and AGO2 but decreased upon co-transfection with YTHDF2 and siAGO2, compared with the control, in ActD-treated A549 and H1299 cells (Additional file 8: Fig. S7g). These observations indicated that YTHDF2-mediated YAP mRNA decay is regulated by m⁶A modification via the AGO2 system.

Next, we explored whether YTHDF2 inhibited the cellular growth, invasion, and EMT by regulating YAP (Additional file 8: Fig. S7h, i). Indeed, overexpression of YAP reversed the YTHDF2-associated inhibition of cellular growth and viability (Fig. 4m, Additional file 8: Fig. S7j), Ki67-positive cell staining (Additional file 8: Fig. S7k), clone formation (Fig. 4n, Additional file 8: Fig. S7l), migration (Fig. 4o, Additional file 8: Fig. S7m), invasion (Additional file 8: Fig. S7n), EMT (Fig. 4p, Additional file 8: Fig. S7o), and YTHDF2-associated promotion of apoptosis (Fig. 4q, Additional file 8: Fig. S7p) in A549 and H1299 cells. These observations indicated that YAP mRNA decay facilitated by YTHDF2 is mediated by the AGO2 system and regulated by m⁶A modification, inhibiting cellular growth, invasion, and EMT of NSCLC cells.

We next explored the mechanism whereby YTHDF1 promoted tumor growth and metastasis by regulating YAP expression in NSCLC. First, we observed that the expressions of YTHDF1 were higher in tumor tissues than in normal tissues (Fig. 5a, Additional file 9: Fig. S8a, b). IHC analysis revealed that YTHDF1 protein levels were gradually increased with increasing grade of tumor species in NSCLC (Fig. 5b). The correlation of individual the protein level of YTHDF1 with pathological grades of NSCLC patients was shown in Table S1 (Additional file 1: Table S1). In addition, the expressions of YTHDF1 were higher in the NSCLC tumor cell lines than that in the control cells BEAS-2B (Additional file 9: Fig. S8c). We also used the publicly available datasets to determine the prognostic correlation between YTHDF1 expression and NSCLC patient survival [27]. The results show that the OS of patients with high YTHDF1 expression (n = 246) was shorter than that of patients with low YTHDF1 expression (n = 246) (P = 0.018) (Fig. 5c). Next, to investigate the function of YTHDF1 in the occurrence and development of NSCLC, we overexpressed YTHDF1 by transfecting A549 and H1299 cells with pcDNA 3.1-YTHDF1, and knocking down of YTHDF1 by siYTHDF1–1 and siYTHDF1–2 (knocking down YTHDF1 using siYTHDF1–2 was more effective than siYTHDF1–1, so siYTHDF1–2 was used to carry out then subsequent experiments) in A549 and H1299 cells (Additional file 9: Fig. S8d, e). Overexpression of YTHDF1 promoted cellular viability (Additional file 9: Fig. S8f), growth (Additional file 9: Fig. S8g, h), migration (Fig. 5d, Additional file 9: Fig. S8i), invasion (Additional file 9: Fig. S8j), and EMT (Fig. 5e, Additional file 9: Fig. S8k), but inhibited apoptosis (Additional file 9: Fig. S8l) of A549 and H1299 cells. The opposite results were seen in A549 and H1299 cells after YTHDF1 was knocked down. Further, TCGA database analysis indicated that YTHDF1 expression was negatively correlated with E-cadherin expression but positively correlated with vimentin expression (Additional file 9: Fig. S8m) in the NSCLC. Furthermore, YTHDF1 overexpression promoted xenograft tumor growth in vivo (Fig. 5f, left panel, Additional file 9: Fig. S8n-p). The similar xenograft tumor metastatic ability and mice survival were obtained in the same mouse group (Fig. 5f, right panel, Additional file 9: Fig. S8q). These observations suggested that YTHDF1 promotes tumor growth and metastasis in NSCLC.

Next, we explored the mechanism whereby YTHDF1 promoted YAP mRNA translation (Fig. 3a). Firstly, we observed that YTHDF1 overexpression increased the protein levels of YAP, CTGF, and Cyr61. However, overexpression of ALKBH5 WT but not ALKBH5 KD reversed the enhanced expression of these genes regulated by YTHDF1 (Fig. 5g, Additional file 10: Fig. S9a). In addition, the protein levels of YAP, CTGF, and Cyr61 were reduced in A549 and H1299 cell co-transfected with YTHDF1 and sieIF3a (eIF3a is a eukaryotic translation initiation factor 3) compared with cells only transfected with YTHDF1 (Fig. 5g, Additional file 10: Fig. S9a). The endogenous co-IP experiments showed that YTHDF1 interacted to eIF3a (Fig. 5h). These data indicated that once YTHDF1 binds to YTHDF3, which binds YAP mRNA containing m⁶A, YTHDF1 presents YAP mRNA to eIF3a-contained translation initiation complex to promote YAP mRNA translation. We then treated A549 and H1299 cells with puromycin dihydrochloride (protein synthesis inhibitor) to evaluate YTHDF1-associated YAP mRNA translation by quantitative ELISA assay. Results showed the YAP mRNA translation was inhibited with increasing concentration of puromycin, while YAP protein levels increased or decreased in puromycin-treated A549 and H1299 cells upon overexpression or knockdown of YTHDF1, respectively, compared with the control vectors (Additional file 10: Fig. S9b). In addition, with increasing puromycin-treatment time, YAP mRNA translation increased or decreased in A549 and H1299 cells transfected with YTHDF1 or siYTHDF1, respectively, compared with the control vectors (Additional file 10: Fig. S9c). Furthermore, YAP mRNA translation increased or decreased in puromycin-treated A549 and H1299 cells co-transfected with YTHDF1, and YTHDF3 or siYTHDF3, respectively, compared with the control (Fig. 5i, Additional file 10: Fig. S9d). The same results were observed for the protein levels of YAP, CTGF, and Cyr61 in these transfected cells (Additional file 10: Fig. S9e). Similar, YAP mRNA translation increased or decreased in puromycin-treated A549 and H1299 cells co-transfected with YTHDF1, and eIF3a or sieIF3a, respectively, compared with the control (Fig. 5j, Additional file 10: Fig. S9f). Further, YTHDF1-associated YAP mRNA translation was increased in cells with increased m⁶A status regulated by shALKBH5 but decreased in cells with reduced m⁶A status regulated by ALKBH5 (Fig. 5k, Additional file 10: Fig. S9g). Finally, m⁶A-mediated YAP mRNA translation increased upon co-transfection into puromycin-treated A549 and H1299 cells with YTHDF1 and eIF3a, but decreased after co-transfection with YTHDF1 and sieIF3a, compared with the control (Additional file 10: Fig. S9h). These findings suggested that YTHDF1/eIF3a-mediated YAP mRNA translation is controlled by m⁶A modification.

Next, we investigated whether YTHDF1 increased NSCLC tumor growth and metastasis by regulating YAP (Fig. 5l, Additional file 10: Fig. S9i). Knockdown of YAP inhibited the YTHDF1-mediated improvement of cellular growth (Additional file 10: Fig. S9j), viability (Additional file 10: Fig. S9k), Ki67-positive cell staining (Additional file 10: Fig. S9l), clone formation (Fig. 5m, Additional file 10: Fig. S9m), migration (Additional file 10: Fig. S9n), invasion (Fig. 5n, Additional file 10: Fig. S9o), EMT (Fig. 5o, Additional file 10: Fig. S9p), and YTHDF1-associated inhibition of apoptosis (Fig. 5p, Additional file 10: Fig. S9q) in A549 and H1299 cells. Moreover, stable knockdown of YAP inhibited xenograft tumor growth mediated by YTHDF1 overexpression in vivo (Fig. 5f, left panel, Additional file 9: Fig. S8o, p). The similar xenograft tumor metastatic ability and mice survival were obtained in the mouse group by stable knockdown of YAP (Fig. 5f, right panel, Additional file 9: Fig. S8q). This indicated that YTHDF1 promotes YAP mRNA translation, which enhances cellular growth, invasion, and EMT of NSCLC cells in vitro and in vivo.

ALKBH5 regulates the expression of Human antigen R (HuR), which is a posttranscriptional regulator of gene expression, played a key role in stabilizing multiple mRNAs in cellular biology [12, 13]. Analysis of information in the TCGA database revealed a positive correlation between ALKBH5 and HuR mRNA levels in NSCLC tissues (Fig. 6a). Further, bioinformatics analysis suggested that ALKBH5 interacts with HuR (Fig. 6b). While overexpression of ALKBH5 caused increase in HuR expression, silencing of ALKBH5 resulted in a significantly decreased expression of HuR in A549 and H1299 cells (Fig. 6c). Interestingly, the expression of HuR was unchanged in A549 and H1299 cells transfected with ALKBH5 KD, compared with the control (Additional file 11: Fig. S10a). We then confirmed the physical interaction between HuR and ALKBH5 by endogenous Co-IP assay in A549 cells (Fig. 6d). These findings indicated that ALKBH5 might be involved in regulating the expression of HuR.

Recent studies have shown that miR-107 regulates proliferation and invasion of gastric adenocarcinoma cells by regulation of LATS2 [31]. However, the underlying mechanism of miR-107 especially in association with tumor growth and metastasis in NSCLC has not been explored. Coupled with that ALKBH5 was involved in regulating the expression of HuR meantime HuR played a key role in stability of multiple RNAs, we assume that ALKBH5 regulate the miR-107 level in an HuR-dependent manner in NSCLC. Importantly, qPCR analysis revealed that HuR repressed the miR-107 expression by regulating its processing (Fig. 6e, Additional file 11: Fig. S10b). It remained to be elucidated whether ALKBH5 regulates miR-107 expression in an HuR-dependent manner. As anticipated, ectopic expression of ALKBH5 inhibited the expression of miR-107 (Fig. 6f); however, this regulation was inhibited by the silencing of HuR (Fig. 6g, Additional file 11: Fig. S10c). Furthermore, silencing ALKBH5 elevated the expression of miR-107, which, in turn, was inhibited by the ectopic expression of HuR (Fig. 6g, Additional file 11: Fig. S10c). These observations indicated that ALKBH5 decreases the miR-107 levels in an HuR-dependent manner.

Since ALKBH5 decreases the miR-107 level, we would seek the specific target gene for miR-107 and explore whether ALKBH5 control the activity of YAP via regulation of miR-107 in NSCLC. Interestingly, according to miRbase, miRanda, and TargetScan database analysis, LATS2, which inhibits the proliferation and migration of tumor via regulating the activity of YAP, is a direct target of miR-107 (Fig. 6h). Dual luciferase reporter assay confirmed that LATS2 is a direct target of miR-107 (Fig. 6i, Additional file 11: Fig. S10d). MS2 binding system (Fig. 6j) and RNA pulldown approach combined with qPCR quantification involving a biotin-labeled probe (Fig. 6k, Additional file 11: Fig. S10e) revealed that miR-107 directly binds to 3′UTR of LATS2. In addition, miR-107 mimics (miR-107 m) inhibited, while miR-107 inhibitors (miR-107 i) elevated, the expression of LATS2 (Fig. 6l, Additional file 11: Fig. S10f, g). In addition, TCGA database analysis revealed a positive correlation between ALKBH5/HuR, which regulate the miR-107 level, and LAST2 in NSCLC tumors (Additional file 11: Fig. S10h). These findings indicated that miR-107 regulation by ALKBH5 reduces the expression of LAST2 in an HuR-dependent manner.

By using western blot and immunofluorescence staining, we showed that LATS2 regulates the activity of YAP by promoting its phosphorylation (Fig. 6m, Additional file 11: Fig. S10i). We also observed that miR-107 mimics reduced the phosphorylation of YAP and increased the nuclear translocation of YAP, increasing YAP activity (as determined by analyzing the expression of CTGF and Cyr61) (Fig. 6n, Additional file 11: Fig. S10j). This suggested that miR-107 increased YAP activity by reducing LAST2 levels in NSCLC. Finally, we explored whether ALKBH5 decreased the activity of YAP via miR-107. Indeed, protein levels of CTGF and Cyr61 were reversed in the A549 and H1299 cells co-transfected with ALKBH5 and miR-107 mimics compared with cells transfected with ALKBH5 alone (Fig. 6o, Additional file 11: Fig. S10k). Furthermore, co-transfection of A549 and H1299 cells with ALKBH5 and miR-107 mimics reversed the ALKBH5-associated inhibition of cell viability and growth (Fig. 6p, Additional file 11: Fig. S10l), invasion and migration (Fig. 6q, Additional file 11: Fig. S10m), and EMT (Fig. 6r, Additional file 11: Fig. S10n). Furthermore, co-transfection of A549 and H1299 cells with ALKBH5 and siLAST2 exerted a similar effect as that of the co-transfection of ALKBH5 and miR-107 on the expression of CTGF and Cyr61 (Additional file 11: Fig. S10o), cell viability (Additional file 11: Fig. S10p), invasion and migration (Additional file 11: Fig. S10q), and EMT (Additional file 11: Fig. S10r).

Collectively, the above findings indicated that ALKBH5 decreases the activity of YAP by regulating miR-107/LATS2 axis in an HuR-dependent manner.

Based on the above findings regarding the roles of ALKBH5, YTHDF1 and miR-107 in NSCLC tumor growth and metastasis, we generated A549 cell lines stably co-expressing shALKBH5 with an empty vector (shALKBH5^Vector), shYTHDF1 with shcontrol (shYTHDF1^shcontrol), shALKBH5 with shYTHDF1 (shALKBH5^shYTHDF1) and a control stable cell line, shcontrol^Vector. We then used these cells to generate a mouse xenograft model. We first analyzed the expression levels of ALKBH5 and YTHDF1 by RT-PCR and qPCR to validate the generated cell lines (Fig. 7a). Approximately 2 weeks after subcutaneous implantation of these cells into mice, larger tumors (Fig. 7b) and faster tumor growth (Fig. 7c) were observed in shALKBH5^Vector group, and opposite in the shYTHDF1^shcontrol group compared with the tumor weight and growth in the shcontrol^Vector group. In addition, shALKBH5^shYTHDF1 decreased the tumor weight and growth compared to the shALKBH5^Vector group (Fig. 7b, c). Additionally, increased survival was observed in the shYTHDF1^shcontrol group, and decreased survival in the shALKBH5^Vector group, compared with the survival in the shcontrol^Vector group (Fig. 7d). The survival was increased in shALKBH5^shYTHDF1 group compared to the shALKBH5^Vector group (Fig. 7d). Moreover, quantitative IHC analysis (n = 5) (Fig. 7e) and qPCR assays (Fig. 7f) of Ki67, YAP, CTGF, Cyr61, and Vimentin expression in the xenografts revealed higher levels of their expressions in the shALKBH5^Vector group than in the shcontrol^Vector group, with lower expression observed for E-cadherin and cleaved caspase 3 levels (Fig. 7e, f, Additional file 12: Fig. S11a, b). The opposite was observed in the shYTHDF1^shcontrol group compared with their expressions in the shcontrol^Vector group (Fig. 7e, f, Additional file 12: Fig. S11a, b). Further, shALKBH5^shYTHDF1 reversed these expressions within the shALKBH5^Vector group (Fig. 7e, f, Additional file 12: Fig. S11a, b). Furthermore, significantly more and larger lung cancer metastatic lesions were observed in the shALKBH5^Vector group, and fewer and smaller metastatic lesions in the shYTHDF1^shcontrol group, compared with the shcontrol^Vector (Fig. 7g). Typically, shALKBH5^shYTHDF1 decreased the tumor metastasis compared with the shALKBH5^Vector group. These observations indicated that ALKBH5 controls tumor growth and metastasis by regulating the expression of YAP in an YTHDF1-dependent manner in vivo.

Next, we generated an A549 cell line stably co-expressing ALKBH5 with a control vector (ALKBH5^control) or miR-107 mimics (ALKBH5^{miR-107 m}), and a control stable cell line, Vector^control, to explore whether miR-107 was involved in the ALKBH5-mediated tumor growth and metastasis. The expression levels of ALKBH5 and miR-107 were analyzed by RT-PCR and qPCR to validate the generated cell lines (Fig. 7h). Larger tumors (Fig. 7i) and faster tumor growth (Fig. 7j) were observed in ALKBH5^{miR-107 m} group than in the ALKBH5^control group. In addition, the survival in the ALKBH5^{miR-107 m} group was decreased compared with that in the ALKBH5^control group (Fig. 7k). The expression of Ki67, CTGF, Cyr61, and Vimentin was increased but that of E-cadherin and cleaved caspase 3 was decreased in the ALKBH5^{miR-107 m} group compared with the ALKBH5^control group, as determined by RT-PCR and IHC analysis (n = 5) (Fig. 7l, m, Additional file 12: Fig. S11c). Further, significantly more and larger lung cancer metastatic lesions were observed in the ALKBH5^{miR-107 m} group than in the ALKBH5^control group (Fig. 7n). These observations indicated that ALKBH5 inhibits tumor growth and metastasis by reducing YAP activity in an miR-107–dependent manner in vivo.

To further explore whether inhibition of m⁶A decreased the tumor growth and metastasis, the m⁶A inhibitor, cycloleucine (CL) [32] which could negatively regulate m⁶A levels by decreasing the S-adenosyl-methionine concentration, was used in this study. Our results showed that cycloleucine significantly decreased the level of YAP m⁶A modification induced by shALKBH5, while not affecting the mRNA expression of ALKBH5 in A549 and H1299 cells (Additional file 12: Fig. S11d-f). In addition, treatment with cycloleucine significantly decreased the cell growth (Additional file 12: Fig. S11g), migration (Additional file 12: Fig. S11h) and EMT (Additional file12: Fig. S11i) in ALKBH5 transfected A549 and H1299 cells compared with treatment with Vehicle. Moreover, we generated A549 cell lines stably co-expressing shALKBH5 with an empty vector (shALKBH5^Vector) and a control stable cell line, shcontrol^Vector, which were treated with cycloleucine (25 mg/kg twice weekly) and vehicle, respectively. Our data showed that the weight and growth of tumors were significantly decreased in the shALKBH5^Vector group with treatment of cycloleucine compared to the vehicle treatment (Fig. 7). Furthermore, quantitative IHC analysis (n = 5) (Fig. 7q, Additional file 12: Fig. S11j) and qPCR (Additional file12: Fig. S11k) assays of Ki67, YAP, CTGF, Cyr61, and Vimentin expression in the xenografts revealed lower levels of their expressions in the cycloleucine-treated than the vehicle--treated shALKBH5^Vector group, with higher expression observed for E-cadherin and cleaved caspase 3 levels (Fig. 7q, Additional file 12: Fig. S11j, k). These finding showed that a pharmacological inhibitor of m⁶A could inhibited tumor growth and metastasis.

Supplementary Table 1 and Figs. S1 to S11 are attached.